1Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer, 2002, 38(Suppl 5):S37-S38.
2Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347: 472-480.
3Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 ( Gleevec ). Cancer, 2002, 95: 881-887.
4Scott LC, White JD, Reid R, et al. Managment of skin toxicity related to the use of imatinib mesylate(STI571 ,Glivec^TM) for advanced stage gastrointestinal stromal tumours. Sarcoma, 2005, 9:157-160.
5Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet, 2004, 364: 1127-1134.
6Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinih mesylate at two dose levels in patients with unreseetable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 2008, 26: 626-632.
7Heinrich MC, Maki R, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant(IM R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol, 2006,24:9502.
8Demetri GD, Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368: 1329-1338.
9Sica DA. Angiogenesis inhibitors and hypertension: an emer ging issue. J Clin Oncol, 2006, 24:1329-1331.
10Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effectsin human rectal cancer. Nat Med, 2004, 10: 145-147.
7Goodman VL, Rock EP. Dagher R, et al. Approval summary:sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma[J].Clin Cancer Res, 2007, 13(5): 1367-1373.
8Socinsld MA, Novello S, BrahmerJR, el at. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer[J].J Clin Oncol, 2008, 26(4): 650-656.
9Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer[J]. BrJ Cancer, 2009, 101(9): 1543-1548.
10Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(6 Suppl 2): S119-S123.
